Story Stocks^®

Johnson & Johnson (JNJ) is trading roughly flat despite reporting solid Q2 upside for both EPS and revenue while raising FY26 EPS and revenue guidance by more than the Q2 beat, implying upside expectations for 2H26. The market appears focused on softer MedTech growth, particularly weakness at Abiomed, following a strong run in the shares heading into earnings. Q2 revenue increased 6.6% yr/yr (+5.6% operational) to $25.31 bln, driven by growth across both the Innovative Medicine and MedTech segments.

• Innovative Medicine: Sales rose 7.8% yr/yr (+6.8% operational) to $16.38 bln, fueled by strong demand for Darzalex, Carvykti, Tecvayli, Rybrevant/Lazcluze, Tremfya, Spravato, and Caplyta, partially offset by Stelara, Remicade, Imbruvica, and Zytiga.
• MedTech: MedTech sales increased 4.5% yr/yr (+3.6% operational) to $8.93 bln, slowing from Q1's 7.7% reported growth as strength in Surgery, Cardiovascular, Vision, and Orthopaedics was offset by weaker Abiomed results. Abiomed sales declined 2% as physicians became more selective in U.S. procedures following a recent external clinical trial, weighing on overall MedTech performance. 
• Guidance: JNJ raised FY26 adjusted EPS guidance to $11.60-11.75 from $11.45-11.65 and increased adjusted operational sales growth guidance to 6.2-6.8% from 5.6-6.6%. The company remains on track to surpass $100 bln in annual revenue for the first time in its 140-year history and highlighted a portfolio of 28 products and platforms each generating more than $1 bln in annual sales.
• Margin tradeoff: The main offset is that management continues to frame margin pressure as deliberate, tied to heavier launch investment and integration spending rather than demand weakness, which means investors still need proof that spending converts into durable operating leverage.

Briefing.com Analyst Insight

Overall, this was a strong quarter, with upside results across the board and a meaningful increase to full-year guidance that suggests management expects momentum to continue through the second half of FY26. Innovative Medicine remains the primary growth engine, with newer oncology and immunology products more than offsetting the ongoing Stelara patent headwind. The lone blemish was MedTech, where slowing growth and a decline at Abiomed raised concerns that procedure trends could remain pressured in the near term. However, management characterized the Abiomed weakness as tied to physician usage patterns following a clinical study rather than a deterioration in the underlying franchise. With the stock having rallied sharply ahead of earnings, expectations were elevated, leaving little room for any disappointment. While today's muted reaction is understandable, we continue to view JNJ's diversified portfolio, deep pipeline, and improving earnings outlook as supportive of longer-term growth, particularly as newer product launches gain traction into 2027.